Alder BioPharmaceuticals appoints Bob Azelby to its Board of Directors as CEO

– USA, WA – Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today named biotech industry veteran Robert W. Azelby president and chief executive officer of Alder, effective June 13, 2018. He also will serve on the company’s board of directors.

Mr. Azelby joins Alder from Juno Therapeutics, Inc., where he served as executive vice president and chief commercial officer. He was responsible for the development and implementation of Juno’s CAR-T commercial strategy. Mr. Azelby was a member of Juno’s executive management team and helped guide the organization through rapid growth and ultimately, to a $9 billionacquisition by Celgene Corporation. He succeeds Paul B. Cleveland, who has been acting as Alder’s interim president and chief executive officer. Mr. Cleveland will continue to serve on the company’s board of directors.

“We are thrilled to have Bob join Alder at this key stage in the company’s history. He is a seasoned leader who brings significant operational experience and a strong track record in both large and small biopharmaceutical environments, and his skills will be of great value as we progress our CGRP inhibitor, eptinezumab, towards approval and commercialization for migraine prevention,” said Mr. Cleveland. “We look forward to Bob’s leadership as we continue to deliver on our commitment to transform the treatment paradigm for migraine prevention to benefit the millions of underserved patients living with migraine and create value for our shareholders.”

“Eptinezumab has the potential to make a significant difference in the lives of people dealing with the debilitating effects of migraine,” Mr. Azelby said. “I am excited to join Alder at this pivotal time for both the company and the migraine community.”

Mr. Azelby brings over 26 years of biopharmaceutical industry expertise. Prior to joining Juno in 2015, Mr. Azelby had a 15-year career of building high-performing teams and creating strong value at Amgen Inc. He joined the company in 2000 in sales and marketing business development and rapidly advanced in the organization where he had nine different roles including an international assignment all with increasing responsibility. In 2012, Mr. Azelby was promoted to vice president and general manager of Amgen’s U.S. oncology business, where he was responsible for a $6.5 billion, ten-product portfolio and a team of over 700 people.

Mr. Azelby began his career in the industry as a sales representative in Philadelphia for the former British drug company Glaxo Welcome PLC. He then worked for Oxford Health Plans, a subsidiary of the healthcare organization Oxford Health, and the medical risk management start-up Avandel Inc. before joining Amgen.

Azelby holds a bachelor’s degree in economics and religious studies from the University of Virginia and earned an MBA from Harvard University.

About Alder BioPharmaceuticals, Inc.

Alder BioPharmaceuticals is a clinical-stage biopharmaceutical company focused on transforming the migraine treatment paradigm through the discovery, development and commercialization of novel therapeutic antibodies. Alder’s lead product candidate, eptinezumab, is a pivotal-stage monoclonal antibody (mAb) that inhibits calcitonin gene-related peptide (CGRP). Eptinezumab is currently in late-stage clinical development and, if approved, will be the first-to-market infusion therapy for migraine prevention. Alder is also developing ALD1910, a preclinical mAb that inhibits pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38) for migraine prevention.

For more information : http://www.alderbio.com

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.